COMMUNIQUÉS West-GlobeNewswire

Heartflow to Report First Quarter 2026 Financial Results on May 14, 2026
23/04/2026
SAN FRANCISCO, April 23, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will release financial results for the [...]
LeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatment-Resistant ER+/HER2-, ESR1-Mutated Metastatic Breast Cancer
23/04/2026
Management to be Joined by Two Clinical Leaders in the Breast Cancer Field Expected to Complete Enrollment in Ongoing ELAINE-3 Phase 3 Registrational Study of Lasofoxifene in Metastatic Breast Cancer in 4Q26 with Data [...]
iTonic Holdings Ltd Granted An Extension of Additional 180-Day by Nasdaq to Regain Compliance with Minimum Bid Price Rule
23/04/2026
BEIJING, China, April 23, 2026 (GLOBE NEWSWIRE) -- iTonic Holdings Ltd (the “Company” or “ITOC”), a healthcare solution provider specializing in treatment planning systems for brachytherapy and other related products [...]
Trevi Therapeutics to Participate in Upcoming May Events
23/04/2026
NEW HAVEN, Conn., April 23, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the [...]
Cytek Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026
23/04/2026
FREMONT, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced that it will report financial results for the first quarter 2026 after market [...]
Weight Watchers Schedules First Quarter 2026 Earnings Conference Call
23/04/2026
NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers” or the “Company”) will release its results for the first quarter 2026 ended March 31, 2026, before market open on [...]
Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors
23/04/2026
WATERTOWN, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and [...]
Kiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026
23/04/2026
LONDON, April 23, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 28, 2026 at 8:30 a.m. Eastern [...]
Coloplast A/S - Coloplast revises financial guidance for FY 2025/26 to reflect reduced growth outlook for Kerecis
23/04/2026
Announcement no. 04/2026 Inside information Coloplast revises the financial guidance on organic growth and EBIT growth in constant currencies before special items for FY 2025/26, reflecting a slower market recovery in [...]
Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.
23/04/2026
Regeneron will provide Otarmeni™ (lunsotogene parvec-cwha) , its recently approved gene therapy for an ultra-rare form of genetic hearing loss, for free in the U.S. Regeneron will lower Medicaid prices based on prices [...]
This Alcohol Awareness Month, Oxford Treatment Center Raises Red Flag, Citing Significant Rise in Patients Seeking Help for Alcohol Addiction
23/04/2026
ETTA, Miss., April 23, 2026 (GLOBE NEWSWIRE) -- With April designated as Alcohol Awareness Month, Oxford Treatment Center, a leading provider of addiction and co-occurring disorder treatment in Mississippi, is sounding [...]
Hormify Launches Transparent, Research-Based Supplement for Hormonal Balance and Daily Wellness
23/04/2026
NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Hormify today announced the introduction of its transparent, research-based dietary supplement formulated to support hormonal balance, mood, and energy. Produced in FDA- [...]
Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104
23/04/2026
FDA Issued Complete Response Letter Citing Outstanding Items Related to Chemistry, Manufacturing, and Controls and Non-Clinical Information FDA Does not Request Additional Clinical Data Company Intends to Resubmit [...]
Progyny, Inc. Announces Details for Its First Quarter 2026 Results Report
23/04/2026
NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, will report its financial results for the quarterly period ended March 31, 2026 [...]
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 mars 2026
23/04/2026
DECLARATION RELATIVE AU NOMBRE DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL DE LA SOCIETE En application de l'article L. 233-8 II du code de commerce et de l’article 222-12-5 du règlement général de l’AMF, les [...]
IMAAVY® (nipocalimab)▼shows over two years of sustained disease control in a broad population with generalised myasthenia gravis (gMG)
23/04/2026
Through 120 weeks of follow-up, nipocalimab delivered sustained clinical improvements and reductions in total IgG in antibody-positive adult patients including anti-AChR+ and anti-MuSK+ Patients achieving sustained [...]
Chiffre d'affaires du 1er trimestre 2026
23/04/2026
Communiqué de presse Le chiffre d’affaires au 31 mars 2026 s’établit à €1 336m , en progression de +4,9% en base organique par rapport au 1 er trimestre 2025 L’ensemble des activités et des régions contribue à la [...]
First-quarter 2026 revenue
23/04/2026
Press release Revenue as at 31 March 2026 stood at €1 , 336m , up +4.9% on an organic basis compared with the first quarter of 2025 All business segments and regions contributed to revenue growth, supported by [...]
Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S.
23/04/2026
Approval in severe-to-profound and profound OTOF -related hearing loss is based on pivotal results of the CHORD trial demonstrating 80% of participants achieved or surpassed a hearing level meeting the primary endpoint [...]

Pages